Absence of Humoral Response After Two-Dose SARS-CoV-2 Messenger RNA Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: A Case Series.
作者信息
Connolly Caoilfhionn M, Boyarsky Brian J, Ruddy Jake A, Werbel William A, Christopher-Stine Lisa, Garonzik-Wang Jacqueline M, Segev Dorry L, Paik Julie J
机构信息
Johns Hopkins University School of Medicine, Baltimore, Maryland.
出版信息
Ann Intern Med. 2021 Sep;174(9):1332-1334. doi: 10.7326/M21-1451. Epub 2021 May 25.
Abstract
摘要
相似文献
1
Absence of Humoral Response After Two-Dose SARS-CoV-2 Messenger RNA Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: A Case Series.风湿性和肌肉骨骼疾病患者接种两剂严重急性呼吸综合征冠状病毒2信使核糖核酸疫苗后无体液免疫反应：病例系列
Ann Intern Med. 2021 Sep;174(9):1332-1334. doi: 10.7326/M21-1451. Epub 2021 May 25.
2
Temporary hold of mycophenolate augments humoral response to SARS-CoV-2 vaccination in patients with rheumatic and musculoskeletal diseases: a case series.霉酚酸临时停药增强风湿性和肌肉骨骼疾病患者对SARS-CoV-2疫苗的体液免疫反应：病例系列
Ann Rheum Dis. 2022 Feb;81(2):293-295. doi: 10.1136/annrheumdis-2021-221252. Epub 2021 Sep 23.
3
SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response.利妥昔单抗治疗患者的新型冠状病毒2型疫苗接种：体液免疫受损但细胞免疫反应可诱导的证据
Ann Rheum Dis. 2021 Oct;80(10):1355-1356. doi: 10.1136/annrheumdis-2021-220408. Epub 2021 May 6.
4
Rituximab, but not other antirheumatic therapies, is associated with impaired serological response to SARS- CoV-2 vaccination in patients with rheumatic diseases.利妥昔单抗而非其他抗风湿疗法，与风湿性疾病患者对SARS-CoV-2疫苗的血清学反应受损有关。
Ann Rheum Dis. 2021 Oct;80(10):1357-1359. doi: 10.1136/annrheumdis-2021-220604. Epub 2021 May 11.
5
High antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in patients with rheumatic and musculoskeletal diseases.风湿性和肌肉骨骼疾病患者对两剂严重急性呼吸综合征冠状病毒2信使核糖核酸疫苗的高抗体反应。
Ann Rheum Dis. 2021 Oct;80(10):1351-1352. doi: 10.1136/annrheumdis-2021-220656. Epub 2021 May 24.
6
Serum antibody response in patients with philadelphia-chromosome positive or negative myeloproliferative neoplasms following vaccination with SARS-CoV-2 spike protein messenger RNA (mRNA) vaccines.接种严重急性呼吸综合征冠状病毒2（SARS-CoV-2）刺突蛋白信使核糖核酸（mRNA）疫苗后，费城染色体阳性或阴性骨髓增殖性肿瘤患者的血清抗体反应。
Leukemia. 2021 Dec;35(12):3578-3580. doi: 10.1038/s41375-021-01457-1. Epub 2021 Nov 5.
7
Time course of antibody concentrations against the spike protein of SARS-CoV-2 among healthy hospital workers up to 200 days after their first COVID-19 vaccination.健康医护人员首次接种新冠疫苗后长达200天内针对新冠病毒刺突蛋白的抗体浓度随时间变化情况。
J Clin Lab Anal. 2022 Jan;36(1):e24175. doi: 10.1002/jcla.24175. Epub 2021 Dec 14.
8
Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine.单剂 SARS-CoV-2 mRNA 疫苗接种后血清阳性者的抗体反应。
N Engl J Med. 2021 Apr 8;384(14):1372-1374. doi: 10.1056/NEJMc2101667. Epub 2021 Mar 10.
9
Serological response in health care workers after a single dose of SARS-CoV-2 vaccine using six automated SARS-CoV-2 antibody assays.健康工作者接种一剂 SARS-CoV-2 疫苗后，使用六种自动化 SARS-CoV-2 抗体检测试剂的血清学反应。
Diagn Microbiol Infect Dis. 2021 Oct;101(2):115486. doi: 10.1016/j.diagmicrobio.2021.115486. Epub 2021 Jul 10.
10
Immunogenicity of a Single Dose of SARS-CoV-2 Messenger RNA Vaccine in Solid Organ Transplant Recipients.mRNA 疫苗在实体器官移植受者中的单剂免疫原性。
JAMA. 2021 May 4;325(17):1784-1786. doi: 10.1001/jama.2021.4385.
引用本文的文献
1
Effect of antecedent B-cell depletion therapy for patients hospitalized with COVID-19 within a single health system: a propensity score analysis.单一医疗系统中接受过前期B细胞耗竭疗法的COVID-19住院患者的疗效：一项倾向评分分析。
Sci Rep. 2025 Mar 20;15(1):9647. doi: 10.1038/s41598-025-94024-y.
2
Efficacy of coronavirus disease 2019 vaccines in patients with rheumatic diseases.2019冠状病毒病疫苗在风湿病患者中的疗效。
Arch Rheumatol. 2023 Feb 2;38(3):419-428. doi: 10.46497/ArchRheumatol.2023.9676. eCollection 2023 Sep.
3
Three doses of COVID-19 mRNA vaccine induce class-switched antibody responses in inflammatory arthritis patients on immunomodulatory therapies.COVID-19 mRNA 疫苗三剂可诱导免疫调节治疗的炎症性关节炎患者发生类别转换抗体应答。
Front Immunol. 2023 Oct 24;14:1266370. doi: 10.3389/fimmu.2023.1266370. eCollection 2023.
4
Safety and tolerability study of sotrovimab (VIR-7831) prophylaxis against COVID-19 infection in immunocompromised individuals with impaired SARS-CoV-2 humoral immunity.索托维单抗（VIR-7831）预防严重急性呼吸综合征冠状病毒2（SARS-CoV-2）体液免疫受损的免疫功能低下个体感染新型冠状病毒肺炎（COVID-19）的安全性和耐受性研究。
Pilot Feasibility Stud. 2023 Jun 16;9(1):100. doi: 10.1186/s40814-023-01325-y.
5
Impact of age and comorbidities on SARS-CoV-2 vaccine-induced T cell immunity.年龄和合并症对SARS-CoV-2疫苗诱导的T细胞免疫的影响。
Commun Med (Lond). 2023 Apr 24;3(1):58. doi: 10.1038/s43856-023-00277-x.
6
Anti-S1/RBD-Specific Antibody Formation After SARS-CoV-2 Vaccination in Elderly Rheumatoid Arthritis Patients: Single-Center Prospective Observational Study.接种 SARS-CoV-2 疫苗后老年类风湿关节炎患者的抗 S1/RBD 特异性抗体形成：单中心前瞻性观察性研究。
J Korean Med Sci. 2023 Apr 10;38(14):e109. doi: 10.3346/jkms.2023.38.e109.
7
Associations of Polymorphisms with Anti-SARS-CoV-2 Spike and Neutralizing Antibody Titers in Japanese Rheumatoid Arthritis Patients Vaccinated with BNT162b2.接种BNT162b2疫苗的日本类风湿性关节炎患者中多态性与抗SARS-CoV-2刺突蛋白及中和抗体滴度的关联
Vaccines (Basel). 2023 Feb 9;11(2):404. doi: 10.3390/vaccines11020404.
8
Humoral and Cellular Immunity to Severe Acute Respiratory Syndrome Coronavirus-2 Vaccination in Patients with Sarcoidosis.结节病患者对严重急性呼吸综合征冠状病毒 2 疫苗接种的体液和细胞免疫。
Balkan Med J. 2023 Jan 23;40(1):34-39. doi: 10.4274/balkanmedj.galenos.2022.2022-8-64. Epub 2022 Dec 9.
9
Equity Considerations in COVID-19 Vaccination Studies of Individuals With Autoimmune Inflammatory Rheumatic Diseases.自身免疫性炎性风湿病患者 COVID-19 疫苗接种研究中的公平性考虑。
Arthritis Care Res (Hoboken). 2023 May;75(5):967-974. doi: 10.1002/acr.25034. Epub 2022 Dec 7.
10
Anti-SARS-CoV-2 Spike Antibody Titers and Neutralizing Antibodies in Vaccinated Rheumatoid Arthritis Patients.接种疫苗的类风湿关节炎患者体内抗SARS-CoV-2刺突抗体滴度和中和抗体情况
Vaccines (Basel). 2022 Aug 21;10(8):1365. doi: 10.3390/vaccines10081365.
Zotero 插件